Rubicon Genomics Reports Robust 2014 Sales Growth

ANN ARBOR, Mich., Feb. 2, 2015 /PRNewswire/ -- Rubicon Genomics, Inc., today reported that sales increased 28% in 2014, fueled by new product introductions and new agreements with distributors in Europe, North Africa, North America and Asia. Rubicon's DNA library preparation products for arrays and Illumina^® next-generation sequencing (NGS) platforms include ThruPLEX^® DNA-seq, PicoPLEX^TM DNA-seq, PicoPLEX WGA kits and TransPLEX^® C-WTA kits. 

In 2014, Rubicon launched its leading ThruPLEX DNA-seq product along with five product line extensions that increase multiplexing options and enable scientists to use ThruPLEX for high throughput applications, while improving sensitivity and reproducibility. The company also moved into a new 19,000 square foot facility in Ann Arbor and added additional employees, including an experienced head of new product development. Four new patents covering Rubicon's DNA library preparation technologies issued in 2014 and multiple new patent applications were filed.

James Koziarz, PhD, CEO of Rubicon Genomics, commented, "Our focus on new products and expansion of our distribution network produced healthy sales increases in 2014, continuing the strong growth trajectory we have experienced over the past few years. We expect our recent investments in R&D, new product development and improved facilities will help accelerate sales growth this year, as the unique value delivered by our DNA library preparation kits becomes better known and our kits become more widely available throughout the rapidly growing genomics sector."

ThruPLEX DNA-seq libraries can be created with as little as 50 picograms of DNA and are especially valuable for challenging specimens such as cell-free, plasma-based DNA. The kits contain all the necessary validated components for preparing libraries, including adaptors and indexing reagents. The workflow is performed in a single tube or well in about two hours and requires no purification or sample transfers. ThruPLEX DNA-seq produces uniform coverage and improves molecular complexity, yielding highly reproducible results. It can be used in any DNA-seq, RNA-seq, or ChIP-seq application and provides robust performance with leading enrichment technologies.

PicoPLEX WGA kits and PicoPLEX DNA-seq kits are recognized as providing the most accurate and reproducible single-cell assays for aneuploidy and CNV determination. PicoPLEX technology revolutionized IVF by enabling pre-implantation genetic screening using arrays and sequencing platforms. PicoPLEX's patented technology is optimized for amplification of genomic DNA with input concentrations of less than six picograms. The single tube protocol reduces handling errors and background while dramatically decreasing time to results. 

TransPLEX C-WTA kits facilitate whole transcriptome analysis on arrays. They are manufactured under cGMP and are available for diagnostic use. TransPLEX C-WTA kits are optimized for amplification of difficult samples such as FFPE. They are currently used in Agendia's FDA-approved Mammoprint^® 70–Gene Breast Cancer Recurrence Assay.

Click here for information on Rubicon products and here for information on distributors.

About Rubicon Genomics    
Rubicon Genomics, Inc. is a leader in the development and commercialization of innovative sample-specific nucleic acid library preparation products used in research and clinical testing on NGS, microarray and q-PCR platforms. The company creates efficient molecular biology tools for genetic, epigenetic and expression analysis of difficult samples to facilitate gene-based research, drug development and diagnostics.  Privately-held Rubicon is located in Ann Arbor, Michigan. For more information, visit rubicongenomics.com. 

SOURCE Rubicon Genomics, Inc.

Related Links

http://www.rubicongenomics.com